Pharma R&D Today
Ideas and Insight supporting all stages of Drug Discovery & Development
Christy J. Wilson
Sr. Director, Pharma and Biotech Segment
Connect with Christy J. Wilson on LinkedIn
Follow Christy J. Wilson on Twitter
About the author:
Christy brings more than 20 years of global life science and healthcare industry experience to her role as Senior Director, Segment Marketing for the biopharmaceutical industry segment at Elsevier. In this capacity she is focused on understanding biopharmaceutical R&D challenges and the implications for Elsevier in terms of market led growth opportunities that will improve productivity and success for industry executives and their teams. She also plays a key role in increasing Elsevier’s share-of-voice and market share through strategic go-to-market planning and execution.
Prior to joining Elsevier, Christy held senior marketing and business development roles in Wolters Kluwer’s Pharma Solutions Business Unit where she was responsible for product management and marketing of the Adis portfolio of drug focused journals and newsletters, pipeline and clinical trials intelligence tools, and pharmacovigilance solutions. During her Wolters Kluwer tenure, Christy also worked in the group’s Healthcare Analytics business, a business that provided powerful data, applications, analytics, and consulting to help companies gain deep insight into the pharmaceutical market.
Christy resides in the greater New York City area and holds an MBA in International Business from DePaul University (Chicago) and a BS in Marketing, from Miami University (Ohio).
Posts by Christy J. Wilson
Posted on May 6th, 2020 in COVID-19
The number of vaccines in the pipeline to battle the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has reached to >70 candidates [1,2]. Many different vaccination strategies are being tested, even a noncoronavirus-specific candidate (Bacille Calmette-Guerin vaccine) [2,3] is being investigated because of its potential to promote a less inflammatory immune response to respiratory pathogens . However, a SARS-Cov-2–specific vaccine will likely be a better strategy.(more…)
Posted on May 1st, 2020 in COVID-19
With the coronavirus disease 2019 (COVID-19) case and death count climbing  despite multiple industry shutdowns and extensive social distancing efforts, it has become clear that a vaccine is required to control the spread of the COVID-19 causative agent, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Many different researchers, institutes and companies specializing in vaccine development across the world have entered the race and announced a candidate, resulting in an astonishingly large number (>70) of vaccines in the pipeline [2,3].(more…)
Posted on March 16th, 2020 in COVID-19
Before the coronavirus disease 2019 (COVID-19) pandemic, no one had ever heard of the causative agent 2019 novel coronavirus (SARS-Cov-2). There were no approved antivirals or vaccines for this virus or for any related coronaviruses (e.g., severe acute respiratory syndrome–associated coronavirus (SARS-CoV) or Middle East respiratory syndrome coronavirus).(more…)
Posted on January 27th, 2020 in Pharma R&D
I’ve found lately that drug and treatment pricing pressure is an absolutely unavoidable topic in the industry. It has been highlighted even more recently due to the fact that this pressing issue is often mentioned by the candidates currently running for president in our upcoming election here in the United States. Knowing how important healthcare costs are to many Americans, most of the presidential hopefuls have been promising that they will use the government to bring down prices if they are elected.(more…)